Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
JAZZ
JAZZ
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
JAZZ News
Jazz Pharmaceuticals to Report Q4 and Full Year 2025 Results
4d ago
PRnewswire
Harmony Biosciences: Financial Success Amidst Challenges
Jan 27 2026
Fool
Harmony's Wakix Drug: Financial Success Amid Controversy
Jan 27 2026
NASDAQ.COM
Zymeworks (ZYME) 2026 Milestones Expected to Drive Long-Term Value with Promising ZW191 Data
Jan 12 2026
NASDAQ.COM
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer to Drive Strategic Development
Jan 08 2026
PRnewswire
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer to Drive Strategic Development
Jan 08 2026
Newsfilter
Jazz Pharmaceuticals Reports Ziihera Trial Shows Significant Survival Benefits
Jan 07 2026
Benzinga
Jazz Pharmaceuticals Reports Positive HERIZON-GEA-01 Trial Results for Ziihera in Cancer Treatment
Jan 07 2026
NASDAQ.COM
Jazz Pharmaceuticals' Ziihera Therapy Significantly Improves Survival in HER2+ Gastric Cancer
Jan 06 2026
Newsfilter
Jazz Pharmaceuticals' Ziihera Therapy Significantly Extends Survival in GEA Patients
Jan 06 2026
PRnewswire
Jazz Pharmaceuticals to Participate in 2026 Investor Events
Dec 17 2025
PRnewswire
Jazz Pharmaceuticals to Participate in 2026 Investor Events
Dec 17 2025
PRnewswire
Jazz Pharmaceuticals Reports EpiCom Trial Interim Results, Significant Behavioral Improvements in Epilepsy Patients
Dec 05 2025
PRnewswire
Jazz Pharmaceuticals' Ziihera Achieves Breakthrough in HER2+ Gastric Cancer Clinical Trials
Dec 02 2025
PRnewswire
Jazz Pharmaceuticals Presents Key Ziihera Data at ASCO GI for HER2+ Cancers
Dec 02 2025
Newsfilter
UBS Lowers Jazz Pharmaceuticals Rating to Neutral, Increases Price Target to $188
Nov 24 2025
Benzinga
Show More News
